LETROZOLE DEXCEL

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

LETROZOLE

Commercializzato da:

DEXCEL LTD, ISRAEL

Codice ATC:

L02BG04

Forma farmaceutica:

FILM COATED TABLETS

Composizione:

LETROZOLE 2.5 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

HAUPT PHARMA MUNSTER GmbH, GERMANY

Gruppo terapeutico:

LETROZOLE

Area terapeutica:

LETROZOLE

Indicazioni terapeutiche:

Letrozole - Dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole - Dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data dell'autorizzazione:

2016-02-29